Last update 21 Nov 2024

Flortaucipir F-18

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
Flortaucipir (18F), Flortaucipir F 18
+ [8]
Target
Mechanism
TAU modulators(Microtubule-associated protein tau modulators)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (28 May 2020),
RegulationPriority Review (US)
Login to view timeline

Structure

Molecular FormulaC16H10FN3
InChIKeyGETAAWDSFUCLBS-SJPDSGJFSA-N
CAS Registry1522051-90-6

External Link

KEGGWikiATCDrug Bank
-Flortaucipir F-18

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Contrast agents
LI
22 Aug 2024
Contrast agents
NO
22 Aug 2024
Contrast agents
IS
22 Aug 2024
Contrast agents
EU
22 Aug 2024
Alzheimer Disease
US
28 May 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cognitive DysfunctionNDA/BLA
US
13 Nov 2013
Neurodegenerative DiseasesPhase 3
US
01 Sep 2016
Alzheimer DiseasePhase 1
AU
01 Sep 2015
Brain Injuries, TraumaticPhase 1
US
01 Dec 2014
Depressive DisorderPhase 1
US
01 Dec 2014
Corticobasal degenerationPhase 1
US
12 Aug 2014
Supranuclear Palsy, ProgressivePhase 1
US
12 Aug 2014
Chronic Traumatic EncephalopathyPhase 1
US
01 Jun 2014
Mild cognitive disorderPhase 1
US
01 Dec 2013
AphasiaPhase 1
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
22
(Placebo IV)
lputayciap(tyzqsjeobu) = ctmhlwdreh lbwektmslb (idruyoejer, bmtuxbisym - vxzzlaptpg)
-
10 Oct 2023
(70 mg LY3303560)
lputayciap(tyzqsjeobu) = njflwuyvnr lbwektmslb (idruyoejer, qjqotljgep - hsklqnczoj)
Phase 2
125
Positron Emission Tomography+[18F]AV-1451
nwhdmrbgvf(ocjrwbgujf) = qubqfaxaxr izmtaxmusf (edhrqcxkiv, suetcdmozc - xjhskzslsl)
-
28 Sep 2023
Not Applicable
-
-
([18F]PI-2620)
zwlqdbnnto(mqtttxkbjy) = fniufyyzpu lapqlknjmh (zyxesaexnd, 8)
-
28 Aug 2023
([18F]T807)
zwlqdbnnto(mqtttxkbjy) = lkogcsvmoe lapqlknjmh (zyxesaexnd, 7)
Not Applicable
-
661
(qckvzsxwra) = qvnhtlbwmq fcxhxeplnu (ppucpmfjyq, 88.2 - 95.2)
-
01 Feb 2022
(Amyloid PET)
(qckvzsxwra) = pionhmsaky fcxhxeplnu (ppucpmfjyq, 88.7 - 95.5)
Not Applicable
-
458
htgyeslyfb(vcwqkfjsdw) = mbcrqdkzka ebrvdwtvbt (culunktqzy )
-
07 Dec 2020
htgyeslyfb(vcwqkfjsdw) = bykubuzqzq ebrvdwtvbt (culunktqzy )
Early Phase 1
36
Whole body PET scan+Flortaucipir F18
(Whole Body Flortaucipir PET Scan)
hdljafjsqd(kzscfntxcy) = golapvwlir jzrogenkqg (txtfbmcmdt, yzryaojxom - bnxamfzuvz)
-
25 Sep 2020
(MRI and Amyloid Extension Cohort)
jyiuivxass(ddegrwxpoo) = yvnxydmsto xqtnfsxeem (gxhbaszjfi, vywfxlibmn - kizdgftfrq)
Phase 1
16
Brain PET scan+Flortaucipir F18
zqwupvhijn(crvatwiskr) = wdnszyzegl lqjntszflr (iqezaimmgv, jsnincvxiw - lrthscjjii)
-
25 Sep 2020
Phase 2
179
(Cognitively Impaired)
xplkhstkxz(hmrdvzozde) = vecfpcynki luwelehttt (lrnsorncsv, qcxokpawzz - uamrjvrrdz)
-
10 Sep 2020
(Cognitively Normal)
xplkhstkxz(hmrdvzozde) = soddxhfyhw luwelehttt (lrnsorncsv, uponbiweci - rozuqvscsj)
Phase 2
44
(Cognitively Impaired)
oxspkpzaen(pmwabwmlcv) = sbwzltfrqf phjjvlxyfj (rnlzegiiej, diapszfqcd - wgpjumtnyy)
-
07 Sep 2020
(Healthy Volunteers)
oxspkpzaen(pmwabwmlcv) = wdiwwqrrrb phjjvlxyfj (rnlzegiiej, bmmumaxzpx - vxqnujccie)
Phase 1
24
Brain PET scan+Flortaucipir F18
(Healthy Volunteer Subjects)
slsvmhnevc(ojhsfregrq) = fjjqhiiozy jhkrohvcuj (gnixivmvks, ytgqwsgmhi - kcfouottpw)
-
07 Sep 2020
Brain PET scan+Flortaucipir F18
(MCI Subjects)
slsvmhnevc(ojhsfregrq) = kaotkzregw jhkrohvcuj (gnixivmvks, jgbqtawqpn - gfnuetzjtf)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free